Back to discover
Disease

Tic Disorders

Late-stage therapeutic developmentEmerging research
MeSHTic Disorders
1
Publications
8
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Methylphenidate hydrochlorideapproved

Approval — Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit… (2025)

Inebilizumabapproved

Approval — Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyeliti… (2022)

Satralizumabapproved

Approval — Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppre… (2021)

Melatoninapproved

Approval — Slenyto is indicated for: treatment of insomnia in children and adolescents aged 2-18 ye… (2018)

Mexiletine hydrochlorideapproved

Approval — Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with no… (2018)

Glycopyrronium bromideapproved

Approval — Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children a… (2016)

Selexipagapproved

Approval — Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH)… (2016)

Glycerol phenylbutyrateapproved

Approval — Ravicti is indicated for use as adjunctive therapy for chronic management of patients&nbs… (2015)

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
1
Active
5
Late-stage
5
Completed
Recently completed

Effects of Ondansetron in Obsessive-compulsive and Tic Disorders

Phase 4 · Completed · NYU Langone Health

A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders

Phase 3 · Completed · Hannover Medical School

A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder

Phase 2 · Completed · China Medical University Hospital

Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

Phase 4 · Completed · NYU Langone Health

Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome

Phase 4 · Completed · Harvey S. Singer

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2025emaApproval — Methylphenidate hydrochloride· Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth Revision (ICD-10) and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptoms. source ↗
2022emaApproval — Inebilizumab· Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1). source ↗
2021emaApproval — Satralizumab· Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive. source ↗
2018emaApproval — Mexiletine hydrochloride· Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. source ↗
2018emaApproval — Melatonin· Slenyto is indicated for: treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and / or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient. treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient. source ↗
2016emaApproval — Glycopyrronium bromide· Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. source ↗
2016emaApproval — Selexipag· Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease. source ↗
2015emaApproval — Glycerol phenylbutyrate· Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes3
  • Attention Deficit Disorder with Hyperactivity1
  • Intellectual Disability1
  • Tic Disorders1
Leading journals1
  • BMC psychiatry1
Leading researchers7
  • Guo Y1
  • Hu R1
  • Li J1
  • Luo H1
  • Luo Q1
  • Tan J1
  • Zhang Z1
Affiliations (unnormalised)1
  • the First Affiliated Hospital of Chongqing Medical University1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythmic, stereotyped motor movements or vocalizations which may be exacerbated by stress and are generally attenuated during absorbing activities. Tic disorders are distinguished from conditions which feature other types of abnormal movements that may accompany another another condition. (From DSM-IV, 1994)

Identifiers
MeSHTic Disorders
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.